These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2324823)

  • 1. Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent.
    Deshpande SV; DeNardo SJ; Kukis DL; Moi MK; McCall MJ; DeNardo GL; Meares CF
    J Nucl Med; 1990 Apr; 31(4):473-9. PubMed ID: 2324823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.
    Camera L; Kinuya S; Garmestani K; Wu C; Brechbiel MW; Pai LH; McMurry TJ; Gansow OA; Pastan I; Paik CH
    J Nucl Med; 1994 May; 35(5):882-9. PubMed ID: 8176477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice.
    Deshpande SV; DeNardo SJ; Meares CF; McCall MJ; Adams GP; Moi MK; DeNardo GL
    J Nucl Med; 1988 Feb; 29(2):217-25. PubMed ID: 3258025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: radiolabeling and animal biodistribution studies.
    Govindan SV; Shih LB; Goldenberg DM; Sharkey RM; Karacay H; Donnelly JE; Losman MJ; Hansen HJ; Griffiths GL
    Bioconjug Chem; 1998; 9(6):773-82. PubMed ID: 9815172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution and dosimetry of pretargeted monoclonal antibody 2D12.5 and Y-Janus-DOTA in BALB/c mice with KHJJ mouse adenocarcinoma.
    Lubic SP; Goodwin DA; Meares CF; Song C; Osen M; Hays M
    J Nucl Med; 2001 Apr; 42(4):670-8. PubMed ID: 11337558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity.
    Kozak RW; Raubitschek A; Mirzadeh S; Brechbiel MW; Junghans RP; Gansow OA; Waldmann TA
    Cancer Res; 1989 May; 49(10):2639-44. PubMed ID: 2785435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody CO17-1A prepared by two bifunctional chelate techniques.
    Lee YC; Washburn LC; Sun TT; Byrd BL; Crook JE; Holloway EC; Steplewski Z
    Cancer Res; 1990 Aug; 50(15):4546-51. PubMed ID: 2164441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.
    Roselli M; Schlom J; Gansow OA; Raubitschek A; Mirzadeh S; Brechbiel MW; Colcher D
    J Nucl Med; 1989 May; 30(5):672-82. PubMed ID: 2785585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and 88Y-Janus-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for 90Y radioimmunotherapy.
    Goodwin DA; Meares CF; Watanabe N; McTigue M; Chaovapong W; Ransone CM; Renn O; Greiner DP; Kukis DL; Kronenberger SI
    Cancer Res; 1994 Nov; 54(22):5937-46. PubMed ID: 7954426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation dosimetry for 90Y-2IT-BAD-Lym-1 extrapolated from pharmacokinetics using 111In-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
    DeNardo GL; O'Donnell RT; Shen S; Kroger LA; Yuan A; Meares CF; Kukis DL; DeNardo SJ
    J Nucl Med; 2000 May; 41(5):952-8. PubMed ID: 10809213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved in vivo stability and tumor targeting of bismuth-labeled antibody.
    Ruegg CL; Anderson-Berg WT; Brechbiel MW; Mirzadeh S; Gansow OA; Strand M
    Cancer Res; 1990 Jul; 50(14):4221-6. PubMed ID: 2364380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the in vivo biodistribution of yttrium-labeled isomers of CHX-DTPA-conjugated monoclonal antibodies.
    Kobayashi H; Wu C; Yoo TM; Sun BF; Drumm D; Pastan I; Paik CH; Gansow OA; Carrasquillo JA; Brechbiel MW
    J Nucl Med; 1998 May; 39(5):829-36. PubMed ID: 9591585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude mice: comparison of stable and chemically labile linker systems.
    Williams LE; Lewis MR; Bebb GG; Clarke KG; Odom-Maryon TL; Shively JE; Raubitschek AA
    Bioconjug Chem; 1998; 9(1):87-93. PubMed ID: 9460550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates.
    Kukis DL; DeNardo GL; DeNardo SJ; Mirick GR; Miers LA; Greiner DP; Meares CF
    Cancer Res; 1995 Feb; 55(4):878-84. PubMed ID: 7850803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the in vivo biodistribution of indium-111 and yttrium-88 labeled dendrimer-1B4M-DTPA and its conjugation with anti-Tac monoclonal antibody.
    Kobayashi H; Wu C; Kim MK; Paik CH; Carrasquillo JA; Brechbiel MW
    Bioconjug Chem; 1999; 10(1):103-11. PubMed ID: 9893971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bis(hydroxamamide)-based bifunctional chelating agent for 99mTc labeling of polypeptides.
    Xu LC; Nakayama M; Harada K; Kuniyasu A; Nakayama H; Tomiguchi S; Kojima A; Takahashi M; Ono M; Arano Y; Saji H; Yao Z; Sakahara H; Konishi J; Imagawa Y
    Bioconjug Chem; 1999; 10(1):9-17. PubMed ID: 9893958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indium-111- and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice.
    Borchardt PE; Quadri SM; Freedman RS; Vriesendorp HM
    J Nucl Med; 1998 Mar; 39(3):476-84. PubMed ID: 9529295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.